485 related articles for article (PubMed ID: 18666824)
1. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
Johnson JA; Li JF; Wei X; Lipscomb J; Irlbeck D; Craig C; Smith A; Bennett DE; Monsour M; Sandstrom P; Lanier ER; Heneine W
PLoS Med; 2008 Jul; 5(7):e158. PubMed ID: 18666824
[TBL] [Abstract][Full Text] [Related]
2. Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.
Nishizawa M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
PLoS One; 2013; 8(12):e83150. PubMed ID: 24358257
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
Nishizawa M; Matsuda M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
PLoS One; 2015; 10(9):e0135941. PubMed ID: 26360259
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.
Metzner KJ; Rauch P; Braun P; Knechten H; Ehret R; Korn K; Kaiser R; Sichtig N; Ranneberg B; van Lunzen J; Walter H
J Clin Virol; 2011 Feb; 50(2):156-61. PubMed ID: 21056001
[TBL] [Abstract][Full Text] [Related]
6. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
7. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
[TBL] [Abstract][Full Text] [Related]
10. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
[TBL] [Abstract][Full Text] [Related]
11. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
[TBL] [Abstract][Full Text] [Related]
12. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
13. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
[TBL] [Abstract][Full Text] [Related]
14. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Mulu A; Maier M; Liebert UG
PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
[TBL] [Abstract][Full Text] [Related]
15. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
16. Diversity of HIV-1 Subtypes and Transmitted Drug-resistance Mutations Among Minority HIV-1 Variants in a Turkish Cohort.
Sarinoglu RC; Sili U; Hasdemir U; Aksu B; Soyletir G; Korten V
Curr HIV Res; 2022; 20(1):54-62. PubMed ID: 34802406
[TBL] [Abstract][Full Text] [Related]
17. HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis.
Buckton AJ; Harris RJ; Pillay D; Cane PA
Antivir Ther; 2011; 16(1):9-16. PubMed ID: 21311104
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
[TBL] [Abstract][Full Text] [Related]
19. Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran.
Memarnejadian A; Menbari S; Mansouri SA; Sadeghi L; Vahabpour R; Aghasadeghi MR; Mostafavi E; Abdi M
PLoS One; 2015; 10(5):e0126955. PubMed ID: 25962088
[TBL] [Abstract][Full Text] [Related]
20. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]